Cited by 1,070Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, Bissan, Banerji, Udai, Workman, Paul·2012·Nature Biotechnology

Open this paper in CoChat — free account

Abstract

Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.

Integrity signals

Registry

Crossref · 10.1038/nbt.2284

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574

Show all 172 references

Research works printed but not linked: 1

Goldie, J.H. & Coldman, A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 901–999 of 999

ecancermedicalscience
Testori, A., Ascierto, P. A., Chiarion‐Sileni, V., Lorenzo, F. D., Pelicci, P. G., & Rossi, C. R. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.440 · Cited by 1
“For success in combination development, there is a significant amount of regulatory work as well as operational discipline [12].”
Background
Molecular Systems Architecture of Fibrotic Lung Microenvironment in Idiopathic Pulmonary Fibrosis
Ayyadurai, V. A. S., Manoharan, Y., & Deonikar, P. (2026) · Cells · doi:10.3390/cells15151364 · Cited by 1
Scalable Multiplexed Drug‐Combination Screening Platforms Using 3D Microtumor Model for Precision Medicine
Zhang, Z., Chen, Y., Urs, S., Chen, L., Simeone, D. M., & Yoon, E. (2018) · Small · doi:10.1002/smll.201703617 · Cited by 50
Resistance to microtubule-stabilising agents following point mutation of human βI-tubulin
Rowe, M. R. (2015) · Figshare · doi:10.26686/wgtn.17011898.v1
Targeting the mTOR signalling pathway for prevention and therapy of tuberous sclerosis in mouse models
Kalogerou, M. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Stellenwert der Bioinformatik für die personalisierte Medizin
Lengauer, T. (2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-013-1819-x · Cited by 1
Ativação da via de sinalização Notch pelos oncogenes RET/PTC e BRAFT1799A no carcinoma papilífero de tiroide e sua influência na diferenciação e proliferação celular.
Yamashita, A. S. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2013.tde-17062013-093409
Exploiting Structure Information for Network Dissimilarity Characterization - Application to Disease Network Analysis and Treatment Prediction
Wong, S. (2014) · YorkSpace (York University)
Methodological Approaches towards Personalised Cancer Medicine
Mints, M. (2015) · Figshare
A novel approach to identify shared fragments in drugs and natural products
Balasubramanya, A., Thapa, I., Bastola, D. K., & Ghersi, D. (2015) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2015.7359746
“As a result of our improved understanding of cancer biology, with some notable exceptions the search for “silver bullet” therapies has now largely been replaced by a quest for novel targets that can be simultaneously modulated by combinatorial therapies [1], [3], akin to what has been accomplished for the treatment of…”
Background
ONCOLYTIC ADENOVIRUS CODING FOR GM-CSF IN TREATMENT OF CANCER
Bramante, S. (2015) · Työväentutkimus Vuosikirja
Exploiting the Dependency of Cancer Cells on Molecular Chaperones
Sharp, S. Y., Howes, J. E., & Workman, P. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849739689-00126
Self-citation
Parallel, independent reversions to an embryonic expressionphenotype in multiple types of cancerPreprint
Hudson, C. M., & Conant, G. C. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/056523
“resequencing or improved drug design and targeting [33] [1] [41].”
Background
Models of Cytokine Dynamics During Cytokine Storms and Synergy During Virus and Drug Combination Therapy
Waito, M. (2016) · The Atrium (University of Guelph)
Exploration Of Cancer Proliferative Signaling In Chemotherapy Drug Resistance And Mdig-Induced Tumorigenesis
Wu, K. H. (2016) · Human Biology
Combination therapeutics
Pal, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805274-7.00011-7
Avaliação da expressão gênica de vias pró-apoptóticas em células-tronco tumorais de linhagem de câncer de mama triplo-negativo tratadas com o fitoestrógeno genisteína, doxorrubicina e radiação ionizante
de Carvalho, F. P. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2017.tde-04012017-164633
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2017) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub3
A Meta-analytic Approach for Testing Evolutionary Hypotheses of Acquired Resistance in Metastatic Cancer
Bhardwaj, K. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-3562
“…targeting synthetic lethal mechanisms (and other nononcogene addiction drugs) within drug combinations, and to determine the extent to which they can be combined successfully with chemotherapy drugs, other targeted agents and immunotherapy without increasing toxicity (Al-Lazikani et al., 2012).”
Background
How to Design Phase I Trials in Oncology
Carter, L., O’Brien, C., Dean, E. J., & Cook, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-71324-3_10
Envolvimento da proteína SAM68 na regulação da proliferação celular em tumores de sistema nervoso central
Leite, C. D. S. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.41.2018.tde-01062018-125847
Investigations into how best to target FGFR2 mutant endometrial cancer
Geng, X. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.123437
Learning a Generative Model of Cancer MetastasisPreprint
Kompa, B., & Coker, B. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1901.06023
“Understanding the genomic basis of cancer will yield better treatments and prognosis for patients [8].”
Background
Combinatorial Therapeutic Discovery Using Perturbational Gene-Expression SignaturesPreprint
Huang, C.-T., Hsieh, C.-H., Chung, Y.-H., Oyang, Y., Huang, H., & Juan, H. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3272241
The Application of Nucleic Acid Amplification Strategies in Theranostics
Jiang, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-7044-1_14
“What’s more, drug resistance, insufficient curative effect, and tumor relapse during therapeutic process are still the huge challengeswhen patients treated by conventional cytotoxic drugs or molecularly targeted therapeutics (Al-Lazikani et al. 2012; Yano et al. 2012), and the efficacy of typical anticancer therapies…”
Background
Application: Screening of Sequential Drug Combinations
Song, S. W. (2019) · Springer theses · doi:10.1007/978-981-13-8094-5_3
Identification and functional characterisation of gene fusions in human cancer cell lines
Chen, E. D. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.40285
Combination Therapies in Solid Tumour Oncology
Vertès, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00020-0 · Cited by 1
emba: R package for analysis and visualization of biomarkers in boolean model ensembles
Zobolas, J., Kuiper, M. T. R., & Flobak, Å. (2020) · The Journal of Open Source Software · doi:10.21105/joss.02583
Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer
Kimble, D. C., Dvergsten, E., Thomeas, V., Karovic, S., Conrads, T. P., & Maitland, M. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.044
In Silico Inference of Synthetic Cytotoxic Interactions from Paclitaxel Responses
Lee, J. H., Lee, K. H., & Kim, J. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031097
“Additionally, due to unpredictable therapeutic effects, most cytotoxic agents are often used in combination therapies [28,29].”
Background
Development of Molecularly Targeted Agents in Early Phase Clinical Trials
Barata, P. C., & Yap, T. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_12
Logical modeling: Combining manual curation and automated parameterization to predict drug synergiesPreprint
Flobak, Å., Zobolas, J., Vázquez, M., Steigedal, T. S., Thommesen, L., Grislingås, A., Niederdorfer, B., Folkesson, E., & Kuiper, M. T. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.28.450165
Nanopulse Stimulation as a Possible Immunotherapy
Beebe, S. J. (2021) · Acta Scientific Medical Sciences · doi:10.31080/asms.2020.05.0966
Viral Drug prediction with Matrix Decomposition and Two-layer Heterogeneous Graph InferencePreprint
Qu, J., Cheng, X.-L., Bian, Z., Ni, T., & Guan, N.-N. (2021) · Research Square · doi:10.21203/rs.3.rs-1063392/v1
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2022) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub4
Onkologika
Ludwig, W.-D., & Schwabe, U. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_37
Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies
Pratima, B. J., & Nalini, N. (2022) · Advances in computational intelligence and robotics book series · doi:10.4018/978-1-7998-8786-7.ch007
Dose-response prediction for in-vitro drug combination datasets: a probabilistic approachPreprint
Rønneberg, L., Kirk, P., & Zucknick, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1465185/v1
Resistance to microtubule-stabilising agents following point mutation of human βI-tubulin
Rowe, M. R. (2015) · doi:10.26686/wgtn.17011898 · Cited by 1
Combination Development
St-Pierre, A., Reyes, M., & Duval, V. (2016) · Springer eBooks · doi:10.1007/978-3-319-39053-6_8
Unbiased Functional Proteomics to Identify Novel Mediators of Tumor Vessel Development
Seaman, M. E. (2014) · doi:10.18130/v3vv5k
Introduction
Pal, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805274-7.00001-4
Information mining in patent filings on injectable antineoplastics as a contribution to Health Policy
Chaves, H. K., da Silveira, C. C. D. F., Antunes, A. M. D. S., & de Magalhães, J. L. (2022) · Research Society and Development · doi:10.33448/rsd-v11i12.33848
Precision Medicine, Diffuse Wickedness
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0003
Selected Examples of Ongoing Large Genotype–Drug Matching Precision Cancer Medicine Trials
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.005.0001
Precision Medicine, Precision Health
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0008
Public Reason, Precision Medicine
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0009
A Provocative Prologue
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.002.0007
Cancer Drugs, 2021
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.005.0002
20 Most Expensive Drugs in the United States, 2021
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.005.0003
Copyright Page
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.002.0003
Precision Medicine
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0001
Rational Democratic Deliberation
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0006
Rational Democratic Deliberation
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0005
Dedication
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.002.0004
Precision Medicine
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0002
Obligatory Social Beneficence
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0007
Dose-response prediction for in-vitro drug combination datasets: a probabilistic approachPreprint
Rønneberg, L., Kirk, P., & Zucknick, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1465185/v2
Avaliação dos efeitos da associação entre sulforafano e vitamina D sobre a citotoxicidade, genotoxicidade, migração celular e modulação da expressão gênica em células humanas tumorais de próstata (DU145 e PC-3)
Rodrigues, K. T. (2022) · doi:10.11606/t.17.2022.tde-29092022-172654
Unpacking the Phosphoproteome
van Alphen, C. (2022) · doi:10.5463/thesis.77
Design, Synthesis, Biological Evaluation and Molecular Docking Studies of 5-fluorouracil-dithiocarbamate Conjugates
Zhan, Y., Wang, Y., Wang, P., Zhu, H., Guo, H., Sun, H., & Liu, M. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230203113746 · Cited by 1
Small Molecule Inhibitors Targeting Methyltransferase-Like (METTL) Proteins Against Hepatocellular Carcinoma: A Comprehensive Drug Repurposing ApproachPreprint
Morshed, M. N., Parvez, M. S. A., Akanda, R. I., Saha, M. K., Fardous, J., & Hosen, M. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.11.532187
“drug resistance and provide new treatments, our predicted two compounds can also be combined with the existing first-line and second-line therapies for hepatocellular carcinoma as this can enhance the efficacy of therapies mediated by targeted drugs [77].”
Background
Data from DLGAP1-AS2–Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma
Nan, Y., Luo, Q., Wu, X., Liu, S., Zhao, P., Chang, W., Zhou, A., & Liu, Z. (2023) · doi:10.1158/0008-5472.c.6514157.v1
Data from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Kebir, S., Ullrich, V., Berger, P., Dobersalske, C., Langer, S., Rauschenbach, L., Trageser, D., Till, A., Lorbeer, F. K., Wieland, A., et al. (2023) · doi:10.1158/1078-0432.c.6532785.v1
Data from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Kebir, S., Ullrich, V., Berger, P., Dobersalske, C., Langer, S., Rauschenbach, L., Trageser, D., Till, A., Lorbeer, F. K., Wieland, A., et al. (2023) · doi:10.1158/1078-0432.c.6532785
Data from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
Coker, E. A., Stewart, A., Özer, B., Minchom, A. R., Pickard, L., Ruddle, R. R., Carreira, S., Popat, S., O'Brien, M. E. R., Raynaud, F. I., et al. (2023) · doi:10.1158/1535-7163.c.6543207
Self-citation
Supplementary Table from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
Coker, E. A., Stewart, A., Özer, B., Minchom, A. R., Pickard, L., Ruddle, R. R., Carreira, S., Popat, S., O'Brien, M. E. R., Raynaud, F. I., et al. (2023) · doi:10.1158/1535-7163.22521870
Self-citation
Data from Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
Coker, E. A., Stewart, A., Özer, B., Minchom, A. R., Pickard, L., Ruddle, R. R., Carreira, S., Popat, S., O'Brien, M. E. R., Raynaud, F. I., et al. (2023) · doi:10.1158/1535-7163.c.6543207.v1
Self-citation
Systems biology and data science in research and translational medicine
Azer, K., Barrett, J. S., Trame, M. N., & Musante, C. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00001-5 · Cited by 1
Data from Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models
Mao, B., & Guo, S. J. (2023) · doi:10.1158/2767-9764.c.6893422.v1
WITHDRAWN: Detection and impact of hypoxic regions in multicellular tumor spheroid cultures formed by head and neck squamous cell carcinoma cells lines
Close, D. A., & Johnston, P. A. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.002
Retracted
AN OVERVIEW OF SCIENTIFIC PRODUCTION ON INJECTABLE ANTINEOPLASTICS IN THE WEB OF SCIENCE DATABASE AS A CONTRIBUTION TO PUBLIC HEALTH MANAGEMENT
Chaves, H. K., Antunes, A. M. D. S., da Silveira, C. C. D. F., & de Magalhães, J. L. (2023) · Problems of Management in the 21st Century · doi:10.33225/pmc/23.18.21
“…needs to be constant, due to the need for new drugs to circumvent the process of resistance acquired by tumor cells, as well as the constant discovery of new metabolic routes that lead to the emergence and maintenance of activity of tumor cells (Al-Lazikani et al., 2012; Holohan et al., 2013).”
Background
Tumor genomics in radiotherapy
Cui, S., Speers, C. W., & Naqa, I. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822000-9.00007-0
Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies
Pratima, B. J., & Nalini, N. (2023) · IGI Global eBooks · doi:10.4018/979-8-3693-3026-5.ch019
Additional file 1 of Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines
Parczyk, J., Ruhnau, J., Pelz, C., Schilling, M., Wu, H., Piaskowski, N. N., Eickholt, B. J., Kühn, H., Danker, K., & Klein, A. (2021) · Figshare · doi:10.6084/m9.figshare.14524716
Tumor necrosis factor receptor–associated protein 1 (TRAP1) inhibitors
Sahu, S. K., Kaur, C., Jain, S., Kumar, T. V., & Vaidya, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00016-4
Prediction and principle discovery of drug combination based on multimodal friendship featuresPreprint
Chen, H., & Zhou, X. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.28.610203
WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in estrogen receptor-positive breast cancerPreprint
He, W., Demas, D. M., Kraikivski, P., Shajahan‐Haq, A. N., & Baumann, W. T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.15.613122
“By targeting multiple pathways involved in cell growth and survival, as well as vulnerabilities within cancer cells, combination treatments can reduce the possibility of resistance development 14,15 .”
Background
Probabilistic analysis of tumor growth inhibition models to Support trial design
Baaz, M., Cardilin, T., Lundh, T., & Jirstrand, M. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111969
SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in TERT promoter mutant cancersPreprint
Tandon, A., & Stern, J. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.18.619052
Rethinking cancer drug synergy prediction: a call for standardization in machine learning applicationsPreprint
Wong, A. M., & Crawford, L. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.24.630216
Dual Inhibitors of CDK4 /6 for Treating Cancer
Toogood, P. L. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch22
Decoding resistance in the age of T6SS warfare
Shikuma, N. J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500342122
Imagedds: A Multi-Modal Deep Learning Model for Drug Synergy Prediction Using Image and Graph Representation LearningPreprint
Huang, A., Xu, J., Long, H., Xiang, H., Yu, X., Meng, Y., Xu, Z., Wang, J., & Jin, S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5152273
Targeting the hyperactive STAT3/5 pathway in cutaneous T-cell lymphoma with the multi-kinase nuclear transporter inhibitor IQDMAPreprint
Dey, S., Sorger, H., Schlederer, M., Perchthaler, I., Metzelder, M. L., Kenner, L., Moriggl, R., & Wolf, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.03.641168
Antitumor and antiproliferative potential of crotoxin in triple negative breast tumors
Marques, D. A. C., Marzocchi, M. C. M., Attié, D., Teixeira, N. A. A., Cristina, A., Felipe, C., Cristina, C. N., & Torqueti, M. R. (2025) · Toxicon · doi:10.1016/j.toxicon.2025.108322
Chemical interactive behaviors of drugs
Chandramore, K. R., Sangle, S. J., Patil, P. P., Ahire, R. S., Sonkamble, S. D., Sandhan, S. S., Wadje, M. V., & Landge, M. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23740-9.00003-x
Treatment of Cervical Cancer with Tumor Homing Peptide LyP-2 Functionalized Liposome Loaded with Cisplatin and Vorinostat
Li, Z., Zhang, J., You, S., Zhang, J., Xie, Z., Zhao, N., & Sun, S. (2025) · Journal of Cluster Science · doi:10.1007/s10876-025-02827-w
SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in TERT promoter mutant cancers
Tandon, A., & Stern, J. L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322961
“This multi-targeted approach ensures a comprehensive blockade of the survival mechanisms in TPM cancer cells and may help to prevent the emergence of resistant tumor cells following therapy, which is a common challenge with monotherapies or even dual-target therapies [37].”
WITHDRAWN: The Golgi Apparatus as an Arbiter of Oncofetal Reprogramming: A Systematic Review and Meta-Analysis Linking Embryonic Germ Layer Origin to the Post-Translational Modification Landscape of CancerPreprint
Ferguson, D. J. (2025) · medRxiv · doi:10.1101/2025.06.29.25330484
Design of combination therapeutics from protein response to drugs in ovarian cancer cellsPreprint
Franz, A., Shen, C., Coscia, F., Munroe, K. J., Charaoui, L., Korkut, A., Mann, M., Luna, A., & Sander, C. (2025) · eLife · doi:10.7554/elife.106729.1
Design of combination therapeutics from protein response to drugs in ovarian cancer cellsPreprint
Franz, A., Shen, C., Coscia, F., Munroe, K. J., Charaoui, L., Korkut, A., Mann, M., Luna, A., & Sander, C. (2025) · eLife · doi:10.7554/elife.106729
Leveraging synthetic genetic array screening to identify therapeutic targets and inhibitors for combatting azole resistance in Candida glabrata
Williams, C. C., & Usher, J. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02522-24
Toward a Unifying Theory of Cancer Based on Informational Entropy ReductionPreprint
Montano, C. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5385814
In silico design and evaluation of a hydrophobic-hydrophilic combinatorial drug systems for targeted breast cancer therapy
Muthumanickam, S., Murugesan, M., Pandi, B., Ramachandran, B., Jegatheswaran, S., Rajkumar, M., & Jeyakanthan, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152499
Molecular-Driven Multi-View Hypergraph Contrastive Learning for Drug-Drug Interaction PredictionPreprint
Li, X., Li, R., Qiao, N., Li, H., Ma, Q., & Guo, S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5397945
Systems biology approach in the detection of cancer
Ghosh, S., Mahajan, A. A., Ghosh, S., Seth, P., Sahoo, S. P., Samant, A., Das, S., Das, S., Dey, A., & Panzade, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33351-4.00018-0
Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent.
Huang, H.-C., Chen, T.-Y., Yeh, T.-Y., Yu, M., Wu, S.-S., Li, G.-Y., Chen, B.-J., Lin, M.-H., Lin, C., Hsu, J.-L., et al. (2025) · Bioorganic chemistry (Print) · doi:10.1016/j.bioorg.2025.108917

Authors: Al-Lazikani, B., Banerji, U., & Workman, P.
Affiliations: Royal Marsden NHS Foundation Trust (GB)
Institute of Cancer Research (GB)
Corresponding author: Banerji, Udai
Workman, Paul
ORCID: Banerji, Udai
Workman, Paul
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 30
Issue: 7
Pages: 679-692
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.2284
OpenAlex: W2061061337
Cited by: 1,070
References: 172
Citations by year: 2026: 63 · 2025: 80 · 2024: 71 · 2023: 73 · 2022: 87 · 2021: 73 · 2020: 80 · 2019: 91 · 2018: 81 · 2017: 76 · 2016: 83 · 2015: 90 · 2014: 69 · 2013: 46 · 2012: 6
FWCI: 5.04
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Funders: NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Cancer Research UK (C309/8992, 11566, C309/A8274)
National Institute for Health and Care Research
National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: combination therapy, targeted cancer therapy, driver mutations, synthetic lethality, tumor vulnerability, precision oncology, acquired drug resistance, de novo resistance, polygenic resistance, cytotoxic chemotherapy
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Combined Modality Therapy, Humans, Neoplasms, Drug Design, Genome, Human, Genetic Heterogeneity, Metabolic Networks and Pathways, Precision Medicine, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combinatorial drug therapy for cancer in the post-genomic era

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks